about
Cost-effectiveness of bortezomib for multiple myeloma: a systematic reviewTotal cost comparison in relapsed/refractory multiple myeloma.Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales.
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cost-effectiveness of lenalidomide in multiple myeloma.
@en
Cost-effectiveness of lenalidomide in multiple myeloma.
@nl
type
label
Cost-effectiveness of lenalidomide in multiple myeloma.
@en
Cost-effectiveness of lenalidomide in multiple myeloma.
@nl
prefLabel
Cost-effectiveness of lenalidomide in multiple myeloma.
@en
Cost-effectiveness of lenalidomide in multiple myeloma.
@nl
P2860
P356
P1476
Cost-effectiveness of lenalidomide in multiple myeloma
@en
P2093
Steve Schey
P2860
P304
P356
10.1586/ERP.10.19
P577
2010-06-01T00:00:00Z